Hot Topic Symposium II: Managing Engineered T Cell Toxicities
The SITC 2014 Hot Topic Symposia Presentation Archive is supported through a generous contribution from Prometheus Laboratories Inc. Access slide decks and video via the links in the schedule below.
|
![]() |
Sunday, November 9, 2014
10:30 am – 10:35 am | Welcome and Overview ![]() ![]() Kristen M. Hege, MD – Celgene Corporation and University of California, San Francisco |
10:35 am – 10:45 am | FDA – History of Immune-Related Adverse Effects from the Regulatory Perspective ![]() Bindu George, MD – U.S. Food and Drug Administration |
10:45 am – 10:55 am | Toxicity and Management after CTL019 Therapy: Update from University of Pennsylvania ![]() David L. Porter, MD – University of Pennsylvania |
10:55 am – 11:05 am | Anti-CD19 CAR T Cells: The Balance of Efficacy and Toxicity ![]() ![]() James N. Kochenderfer, MD – National Cancer Institute |
11:05 am – 11:15 am | Memorial Sloan-Kettering Cancer Center Experience Jae H. Park, MD – Memorial Sloan-Kettering Cancer Center |
11:15 am – 11:25 am | Fred Hutchinson Cancer Research Center Experience ![]() ![]() Michael C.V. Jensen, MD – University of Washington |
11:25 am – 11:35 am | Cytokine Storm in T Cell Studies - An Update from Baylor University ![]() ![]() Helen E. Heslop, MD – Baylor College of Medicine |
11:35 am – 12:00 pm | Panel Discussion |
The SITC Hot Topic Symposia are non-accredited continuing medical education events. No credits are offered
for physician participation in these educational programs.
All presentations are licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.